Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Previously Treated ◽

Locally Recurrent

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

Annals of Oncology ◽

10.1093/annonc/mdx505 ◽

2018 ◽

Vol 29 (1) ◽

pp. 154-161 ◽

Cited By ~ 70

Author(s):

H.S. Han ◽

V. Diéras ◽

M. Robson ◽

M. Palácová ◽

P.K. Marcom ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Locally Recurrent

START: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306)

Annals of Oncology ◽

10.1093/annonc/mdy272.356 ◽

2018 ◽

Vol 29 ◽

pp. viii120 ◽

Cited By ~ 1

Author(s):

H. Bonnefoi ◽

C. Levy ◽

G. MacGrogan ◽

T. Grellety ◽

B. Asselain ◽

...

Keyword(s):

Breast Cancer ◽

Androgen Receptor ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Locally Recurrent

Randomized phase II study of capecitabine with or without ramucirumab (IMC-1121B) or IMC-18F1 in patients with unresectable, locally advanced or metastatic breast cancer (mBC) previously treated with anthracycline and taxane therapy (CP20-0903/NCT01234402).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.tps151 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. TPS151-TPS151 ◽

Cited By ~ 1

Author(s):

L. T. Vahdat ◽

K. Miller ◽

J. A. Sparano ◽

H. Youssoufian ◽

J. D. Schwartz ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer

The Oncologist ◽

10.1634/theoncologist.2016-0265 ◽

2017 ◽

Vol 22 (3) ◽

pp. 245-254 ◽

Cited By ~ 7

Author(s):

Linda T. Vahdat ◽

Rachel Layman ◽

Denise A. Yardley ◽

William Gradishar ◽

Mohamad A. Salkeni ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

A Three-Arm Randomized Phase II Study of Oral Vinorelbine Plus Capecitabine Versus Oral Vinorelbine and Capecitabine in Sequence Versus Docetaxel Plus Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines

The Breast Journal ◽

10.1111/tbj.12098 ◽

2013 ◽

Vol 19 (3) ◽

pp. 240-249 ◽

Cited By ~ 10

Author(s):

Mario Campone ◽

Natalya Dobrovolskaya ◽

Serjei Tjulandin ◽

Shin-Chen Chen ◽

Sameul Fourie ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Oral Vinorelbine ◽

Sequence Versus ◽

Randomized Phase Ii ◽

Randomized phase II study of single-agent epirubicin +/— verapamil in patients with advanced metastatic breast cancer

Annals of Oncology ◽

10.1093/oxfordjournals.annonc.a058356 ◽

1993 ◽

Vol 4 (1) ◽

pp. 45-50 ◽

Cited By ~ 35

Author(s):

K. Mross ◽

C. Bohn ◽

L. Edler ◽

W. Jonat ◽

W. Queisser ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

Metastatic Breast ◽

Randomized Phase Ii

PD01-01: Randomized Phase II Trial of Fulvestrant with or without Dasatinib in Postmenopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor.

10.1158/0008-5472.sabcs11-pd01-01 ◽

2011 ◽

Cited By ~ 6

Author(s):

GL Wright ◽

J Blum ◽

LK Krekow ◽

KJ McIntyre ◽

ST Wilks ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Randomized Phase Ii ◽

P5-19-02: Comparison of the Incidence of Peripheral Neuropathy with Eribulin Mesylate Versus Ixabepilone in Metastatic Breast Cancer Patients: A Randomized Phase II Study.

10.1158/0008-5472.sabcs11-p5-19-02 ◽

2011 ◽

Cited By ~ 1

Author(s):

L Vahdat ◽

P Gopalakrishna ◽

AA Garcia ◽

C Vogel ◽

C Pellegrino ◽

...

Keyword(s):

Breast Cancer ◽

Peripheral Neuropathy ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Eribulin Mesylate ◽

Randomized Phase Ii

Abstract GS2-07: MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer

10.1158/1538-7445.sabcs17-gs2-07 ◽

2018 ◽

Cited By ~ 9

Author(s):

P Schmid ◽

M Zaiss ◽

C Harper-Wynne ◽

M Ferreira ◽

S Dubey ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase Ii ◽

Mtor Inhibitor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Estrogen Receptor Positive

Abstract PD3-08: A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab

10.1158/1538-7445.sabcs17-pd3-08 ◽

2018 ◽

Cited By ~ 4

Author(s):

B Xu ◽

F Ma ◽

Q Ouyang ◽

W Li ◽

Z Jiang ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Her2 Positive ◽

Randomized Phase Ii ◽